Dicerna Pharmaceuticals Inc (DRNA) SEC Filing 8-K Material Event for the period ending Monday, October 22, 2018

Dicerna Pharmaceuticals Inc

CIK: 1399529 Ticker: DRNA

View differences made from one to another to evaluate Dicerna Pharmaceuticals Inc's financial trajectory

Compare SEC Filings Year-over-Year (YoY) and Quarter-over-Quarter (QoQ)
Sample 10-K Year-over-Year (YoY) Comparison

Compare this 8-K Corporate News to its predecessor by reading our highlights to see what text and tables were  removed  ,   added    and   changed   by Dicerna Pharmaceuticals Inc.


Assess how Dicerna Pharmaceuticals Inc's management team is paid from their Annual Proxy

Definitive Proxy Statement (Form DEF 14A)
Screenshot example of actual Proxy Statement

Dicerna Pharmaceuticals Inc's Definitive Proxy Statement (Form DEF 14A) filed after their 2018 10-K Annual Report includes:

  • Voting Procedures
  • Board Members
  • Executive Team
  • Salaries, Bonuses, Perks
  • Peers / Competitors


SEC Filing Tools
Ticker: DRNA
CIK: 1399529
Form Type: 8-K Corporate News
Accession Number: 0001193125-18-305870
Submitted to the SEC: Wed Oct 24 2018 6:30:58 AM EST
Accepted by the SEC: Wed Oct 24 2018
Period: Monday, October 22, 2018
Industry: Pharmaceutical Preparations
  1. New Agreement
  2. Unregistered Sales

External Resources:
Stock Quote
Social Media

Bookmark the Permalink: